Physician profile
Nora Gindi-Reed
NPI 1194882126
$1,799.97
in general payments reported to CMS, 2019-2025
12 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Pediatrics (Optometrist) provider received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $45.86 · 2021: $50.04 · 2022: $312 · 2023: $455 · 2024: $538 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174 · Consulting Fee: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.52 |
| Consulting Fee | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $961.33 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $247.49 | 2023-2025 | Clareon, Rhopressa, Simbrinza |
| Tarsus Pharmaceuticals, INC. | $147.68 | 2024 | Xdemvy |
| Dompe US, INC. | $113.14 | 2024 | Oxervate |
| Abbvie INC. | $99.21 | 2024 | |
| Abb Con-Cise Optical Group LLC | $90.24 | 2019-2020 | |
| Oyster Point Pharma, INC. | $50.48 | 2023-2024 | Tyrvaya, Ryzumvi |
| Visioneering Technologies, INC. | $29.64 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.83 | 2019 | |
| Sight Sciences, INC. | $15.63 | 2024 | Tearcare System |
| Kala Pharmaceuticals, INC. | $14.33 | 2022 | |
| Coopervision INC. | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Gindi-Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.